Pfizer (NYSE:PFE) Stock Rating Upgraded by Wall Street Zen

Pfizer (NYSE:PFE) was upgraded by Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued to investors on Sunday, Wall Street Zen reports.

Several other equities analysts also recently commented on PFE. Guggenheim decreased their target price on Pfizer from $35.00 to $31.00 and set a “buy” rating on the stock in a research report on Friday, August 7th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a report on Monday, July 6th. Royal Bank Of Canada upgraded Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price objective on the stock in a research report on Tuesday, June 9th. HSBC lifted their target price on Pfizer from $28.00 to $30.00 and gave the stock a “hold” rating in a report on Thursday. Finally, BMO Capital Markets reduced their target price on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $28.39.

Pfizer Stock Performance

PFE opened at $27.74 on Friday. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. Pfizer has a 12-month low of $23.58 and a 12-month high of $29.21. The business has a 50 day moving average of $26.43 and a 200-day moving average of $26.37. The stock has a market cap of $158.11 billion, a price-to-earnings ratio of 36.50, a PEG ratio of 1.86 and a beta of 0.34.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The business had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same period in the previous year, the firm earned $0.78 EPS. The firm’s revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities research analysts expect that Pfizer will post 2.98 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of PFE. Angeles Wealth Management LLC boosted its stake in shares of Pfizer by 2.2% in the second quarter. Angeles Wealth Management LLC now owns 17,009 shares of the biopharmaceutical company’s stock worth $410,000 after acquiring an additional 358 shares during the period. Manchester Financial Inc. boosted its position in shares of Pfizer by 2.9% during the 2nd quarter. Manchester Financial Inc. now owns 13,168 shares of the biopharmaceutical company’s stock valued at $317,000 after acquiring an additional 365 shares during the last quarter. Vermillion Wealth Management Inc. grew its stake in shares of Pfizer by 19.4% in the 1st quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company’s stock worth $66,000 after buying an additional 382 shares in the last quarter. Eagle Capital Management LLC grew its position in Pfizer by 0.3% in the first quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company’s stock worth $3,554,000 after acquiring an additional 390 shares in the last quarter. Finally, Delta Financial Advisors LLC increased its position in shares of Pfizer by 1.6% during the 1st quarter. Delta Financial Advisors LLC now owns 25,266 shares of the biopharmaceutical company’s stock valued at $709,000 after purchasing an additional 398 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Analysts at Wall Street Zen upgraded Pfizer, providing a favorable near-term sentiment signal, although the available report does not specify the new rating or price target. Pfizer Upgraded at Wall Street Zen
• Positive Sentiment: Pfizer’s new products, acquisitions and late-stage pipeline could help offset COVID-product declines and support renewed growth from 2029, offering a longer-term bull case for the stock. Can Pfizer Overcome Its COVID and Patent Cliff Headwinds?
• Positive Sentiment: Management’s presentation at Morgan Stanley’s 24th Annual Global Healthcare Conference gives investors an updated opportunity to assess Pfizer’s strategy, pipeline and response to its patent and revenue challenges. Pfizer Morgan Stanley Healthcare Conference Transcript
• Neutral Sentiment: Pfizer is highlighted as a high-yield dividend stock, with a roughly 6% yield that may appeal to income-focused investors and tax-advantaged accounts. High-Yield Dividend Stocks Worth Having in Your Roth IRA
• Negative Sentiment: COVID-product revenue is falling, while major drugs face a patent cliff. The resulting earnings pressure could persist before pipeline launches and acquisitions materially contribute to growth. Pfizer COVID and Patent Cliff Headwinds
• Negative Sentiment: Commentary warns that Pfizer’s dividend may be vulnerable if cash flow weakens, as patent losses and balance-sheet constraints leave limited room for execution mistakes. Pfizer’s 6% Yield Masks a Fragile Dividend Story
• Negative Sentiment: A dispute with Poland and Romania over approximately $2 billion of unwanted COVID-19 vaccines adds legal and financial uncertainty. Pfizer Dispute Over Unwanted COVID-19 Vaccines

Pfizer Company Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its portfolio addresses a range of therapeutic areas, including oncology, inflammation and immunology, internal medicine, hospital care, rare diseases and infectious diseases. The company serves patients and healthcare providers in markets worldwide.

Pfizer’s products include the Comirnaty COVID-19 vaccine, the Prevnar family of pneumococcal vaccines, and medicines such as Eliquis, Ibrance, Vyndaqel and Zavzaret.